Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:26:18 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CRVS - CORVUS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRVS - Q0.418.00·22.360.120.46+1.407.31,708.133,78711,91219.06  20.777  19.0626.95  2.5419:42:32Jan 2315 min RT 2¢

Recent Trades - Last 10 of 11912
Time ETExPriceChangeVolume
19:42:32Q20.491.431
18:29:00Q20.491.4310
17:29:33Q20.601.541
17:18:17Q20.581.5215
17:05:41Q20.000.941
16:52:25Q20.56411.5041100
16:28:37Q20.191.132
16:27:14Q20.000.945
16:17:43Q20.000.942
16:10:04Q20.461.401

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-23 17:00U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
2026-01-21 22:54U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2026-01-20 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-01-20 07:00U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
2026-01-16 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
2026-01-05 08:30U:CRVSNews ReleaseCorvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
2025-12-08 10:30U:CRVSNews ReleaseCorvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
2025-11-04 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
2025-11-03 09:02U:CRVSNews ReleaseCorvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
2025-10-31 07:30U:CRVSNews ReleaseCorvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-10-28 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
2025-10-17 10:00U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
2025-10-02 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals Appoints David Moore to Board of Directors
2025-08-07 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
2025-07-31 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
2025-06-25 08:00U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
2025-06-11 07:00U:CRVSNews ReleaseCorvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
2025-06-04 07:00U:CRVSNews ReleaseCorvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
2025-05-28 16:01U:CRVSNews ReleaseCorvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
2025-05-08 16:02U:CRVSNews ReleaseCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results